MNKD: Strong early adoption of new products and pipeline progress set the stage for future growth
Three major catalysts—Afrezza pediatric approval, FUROSCIX autoinjector launch, and MNKD-201 phase I-B data—are driving focus on commercial execution and pipeline advancement. Early ReadyFlow adoption and targeted Afrezza pediatric strategies are showing promise, while MNKD-201 phase II aims for 20…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.